In Table 1, we indicate the operative mechanisms of action of MIF and D-DT in MS, Alzheimer disease and glioblastoma and potential therapeutic anti-MIF/D-DT drugs that could block their pathogenic effects. This evidence concerns the gene MIF and myeloid sarcoma.